Main Business: Research and development and industrialization of small nucleic acid drugs. Leveraging the strong advantage of returnee experts, with original innovation as the main focus, supplemented by introduction-absorption-reinnovation, forming the core competitiveness of a drug R&D enterprise. With the first-mover advantage of being domestic-leading, Asia-leading, and internationally positioned, through short-, medium-, and long-term product portfolios and technology transfer and other profit models, bringing core small nucleic acid drugs to market, becoming a leading enterprise in the national small nucleic acid pharmaceutical field.
Expert Team: Founded in 2006 by a returnee research and management team led by Dr. Zhu Yuanyuan, a national "*" expert. It has gathered a world-class scientist team. Key technology returnee experts come from Silicon Valley in the United States and first-class biopharmaceutical companies in North America, possessing their own research specialties and key core technologies in their respective research fields. With the corporate culture and humanistic environment of "innovation, cohesion, co-creation, win-win", a group of high-level talents has emerged, with national "*" experts leading, provincial ("Mass Innovation and Entrepreneurship" talents) managing, municipal ("Jianghai Talents") deploying, and a postdoctoral workstation as the foundation, forming a strong talent echelon (8 returnee experts, nearly 20 doctoral and master's degree holders), known as a "talent highland" and a model of "those who gain talent gain the world".
Technology Platform: Established a complete small nucleic acid drug development technology chain at a leading level, including drug target construction, drug target screening, structural modification, industrial synthesis, delivery systems, in vivo efficacy evaluation, and quantitative production, forming a "more, faster, better, more economical" small nucleic acid drug development system, filling multiple domestic and international gaps. Invented and applied for more than 40 domestic and international patents.
R&D Achievements: Currently developing 8 strains of small nucleic acid drugs for hepatitis, liver cancer, age-related macular degeneration, skin hyperpigmentation, nasopharyngeal cancer, bladder cancer, and cervical cancer, among which the drug for treating hepatitis has made breakthrough progress. Developed over a thousand research reagents and technical services. In terms of livelihood products, together with Jiangsu Jikang Biotechnology (a subsidiary in which BioMab holds shares), it took the lead globally in launching small nucleic acid skin whitening and freckle removal products, validating the Nobel Prize mechanism, filling domestic and international gaps, and seizing the high ground of industrialization; also includes nucleic acid anti-acne products and cervical cancer diagnostic reagents. All the above products are self-developed patented products.
Management Experience: One of the company's founders, Chairman/President Dr. Zhu Yuanyuan, was among the first batch of national "*" recipients in 2009. He has served in core scientific research and senior management positions at multiple biopharmaceutical/technology companies in the United States, with 20 years of scientific research and management experience in high-tech enterprises in Silicon Valley, USA. After returning to Jiangsu to start a business, he was awarded honorary titles such as the province's "Top Ten" entrepreneurial new overseas Chinese and Overseas Chinese Community Star. Other key executives of the company also have many years of management experience in R&D, management, production, and quality assurance at similar companies domestically and internationally.
Hardware Facilities: The company is located in Nantong Economic and Technological Development Zone, with a registered capital of USD 12.12 million and a total investment of USD 25 million. It has a self-built 10,000 M2 R&D and industrialization base, with 100 mu of self-owned industrial land. The company's laboratory chain, industry chain, and internal environment are seamlessly aligned with European and American companies.
Qualifications and Honors: The company was selected as a national "Twelfth Five-Year Plan" key small nucleic acid major new drug creation base. It has been rated as a high-tech enterprise, a national postdoctoral research workstation, a China Overseas Chinese Contribution Award winner, a key innovation and entrepreneurship team of the Overseas Chinese Affairs Office of the State Council, a Jiangsu Provincial Engineering Technology Research Center, a provincial science and technology innovation team, a provincial small nucleic acid drug engineering technology research center, a provincial small nucleic acid industry technology innovation alliance, a provincial outstanding overseas Chinese-funded enterprise, and a provincial key service enterprise for overseas Chinese and Hong Kong-funded enterprises. It has passed ISO13485 international quality system certification. It was selected for the "2013 Asian Emerging Enterprise Award" (one of the top eight).
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows